The landscape of Alzheimer’s disease (AD) research is undergoing a structural transformation. For decades, therapeutic development dominated investment and innovation. Today, diagnostic development is emerging as the next major growth wave — driven by biology, clinical demand, and regulatory evolution. For biotech innovators, this shift presents both opportunity and urgency. The Transition From Symptom-Based to…

Interleukin-12 is one of the most powerful cytokines in cancer immunotherapy, capable of activating CD8⁺ T cells and NK cells and reshaping the tumor microenvironment. Yet for decades, its clinical use has been constrained by systemic toxicity and short in-vivo half-life when delivered as recombinant protein. In the cmRNA1210 program from Suzhou CureMed and Purecodon,…

Alzheimer’s diagnostics are undergoing one of the most significant transformations in decades. What once required PET imaging or invasive CSF collection is rapidly moving toward simple blood‑based assays powered by ultrasensitive detection of core biomarkers: pTau, Aβ42/40, GFAP, and NfL.This shift isn’t just about convenience. It’s about accessibility, scalability, and earlier detection—the three pillars that…

Bispecific antibodies (BsAbs) are an emerging class of engineered biologics designed to simultaneously bind two distinct antigens or epitopes. By enabling dual-target engagement, bispecific antibodies offer unique mechanisms of action that extend beyond conventional monoclonal antibodies, particularly in oncology and immuno-oncology. In recent years, advances in protein engineering, manufacturing, and clinical development have accelerated the…